Uwe D. Staerz, M.D., Ph.D., Chairman and Chief Scientific Officer, received his M.D. degree from the Eberhard-Karls-Universitaet, Tuebingen, Germany, and a Ph.D. in Molecular Biology / Immunology from the University of California, San Diego, CA. He did a general internship in Medicine, joined a clinical pathology group prior to taking up positions as Research Fellow at The Scripps Research Institute, La Jolla, CA, then as Independent Member of the Basel Institute for Immunology, Basel, Switzerland and as faculty member (through the rank of Full Professor) at the Integrated Department of Immunology, National Jewish Health / University of Colorado Health Sciences Center, Denver, CO. Having founded Greffex, Inc. and its research sister company Isogenis, Inc., he left academia to guide the companies' R&D efforts. He has received numerous NIH (and other Federal) funding since 1990. He has established different research programs, published widely in highly regarded scientific journals and has been inventor of several patents including those providing the underpinning of the GreVac platform. Some of his inventions, T cell-recruiting bispecific antibodies have reached the clinical trial stage.
· The potency and functionality of our platform with data from studies with highly pathological avian influenza (HPAI) and MERS-CoV vaccines